Method for identification of condition-associated public antigen receptor sequences

Mikhail V. Pogorelyy, Anastasia A. Minervina, Dmitriy M. Chudakov, Ilgar Z. Mamedov, Yury B. Lebedev, Thierry Mora, Aleksandra M. Walczak

1 Department of genomics of adaptive immunity, IBCH RAS, Russia; 2 Center for Data-Intensive Biomedicine and Biotechnology, Skoltech, Russia; 3 Central European Institute of Technology, CEITEC, Czech republic; 4 Biological faculty, Moscow State University, Russia; 5 Laboratoire de physique statistique, CNRS, Sorbonne Université, Université Paris-Diderot, and École normale supérieure (PSL University), Paris, France; 6 Laboratoire de physique théorique, CNRS, Sorbonne Université, and École normale supérieure (PSL University), Paris, France

For correspondence:
lebedev_yb@mx.ibch.ru (YBL); tmora@lps.ens.fr (TM); awalczak@lpt.ens.fr (AMW)

*These authors contributed equally to this work

Abstract
Diverse repertoires of hypervariable immunoglobulin receptors (TCR and BCR) recognize antigens in the adaptive immune system. The development of immunoglobulin receptor repertoire sequencing methods makes it possible to perform repertoire-wide disease association studies of antigen receptor sequences. We developed a statistical framework for associating receptors to disease from only a small cohort of patients, with no need for a control cohort. Our method successfully identifies previously validated Cytomegalovirus and type 1 diabetes responsive TCRβ sequences.

Introduction
T-cell receptors (TCR) and B-cell receptors (BCR) are hypervariable immunoglobulins that play a key role in recognizing antigens in the vertebrate immune system. TCR and BCR are formed in the stochastic process of V(D)J recombination, creating a diverse sequence repertoire. These receptors consist of two hypervariable chains, the α and β chains in the case of TCR. Progress in high throughput sequencing now allows for deep profiling of TCRα and TCRβ chain repertoires, by establishing a near-complete list of unique receptor chain sequences, or “clonotypes”, present in a sample. Most sequencing data available correspond to TCRβ only, but the same principles discussed below apply to TCRα repertoires, or to paired αβ repertoires.

Comparison of sequenced repertoires has revealed that in any pair of individuals, large numbers of TCRβ sequences have the same amino acid sequence Venturi et al. (2011). Several mechanisms leading to the repertoire overlap have been identified so far. The first mechanism is convergent recombination. Due to biases in V(D)J recombination process, the probability of generation of some TCRβ sequences is very high, making them appear in almost every individual multiple times and repeatedly sampled in repertoire profiling experiments Britanova et al. (2014). This sharing does not result from a common specificity or function of T-cells corresponding to the shared TCRβ clonotypes, and may in fact correspond to cells from the naive compartment in both donors Quigley et al. (2010), or from functionally distinct subsets such as CD4 and CD8 T-cells. The second possible reason for TCR sequence sharing is specific to identical twins, who may share T cell clones as a
consequence of cord blood exchange in utero via a shared placenta Pogorelyy et al. (2017). Note that in that scenario both the β and α chains are shared together. The third and most interesting mechanism for sharing the sequence of either the β or α or both chains is convergent selection in response to a common antigen. From functional studies, such as sequencing of MHC-multimer specific T-cells, it is known that the antigen-specific repertoire is often biased, and the same antigen-specific TCR β or α chain sequences can be found in different individuals Miles et al. (2011); Dash et al. (2017); Glanville et al. (2017).

Reproducibility of a portion of the antigen-specific T-cell repertoire in different patients creates an opportunity for disease association studies using TCRβ repertoire datasets Faham et al. (2017); Emerson et al. (2017). These studies analyse the TCRβ sequence overlap in large cohorts of healthy controls and patients to identify shared sequences overrepresented in the patient cohort. Here we propose a novel computational method to identify clonotypes which are likely to be shared because of selection for their response to a common antigen, instead of convergent recombination. Our approach is based on a mechanistic model of TCR recombination and is applicable to small cohorts of patients, without the need for a healthy control cohort.

Results
As a proof of concept, we applied our method to two large publicly available TCRβ datasets from Cytomegalovirus (CMV)-positive Emerson et al. (2017) and type 1 diabetes (T1D) Seay et al. (2016) patients. In both studies the authors found shared public TCRβ clonotypes that are specific to CMV-peptides or self-peptides, respectively. Specificity of these clonotypes was defined using MHC-multimers. We show that TCRβ chain sequences functionally associated with CMV and T1D in these studies are identified as outliers by our method.

The main ingredient of our approach is to estimate the probability of generation of shared clonotypes, and to use this probability to determine the source of sharing (see Fig. 1). Due to the limited sampling depth of any TCR sequencing experiment, chances to sample the same TCRβ clono-
type twice are low, unless this clonotype is easy to generate convergently, with many independent
generation events with the same TCRβ amino acid sequence in each individual (convergent recom-
bination), or if corresponding T-cell clone underwent clonal expansion, making its concentration
in blood high (convergent selection). Thus, we reasoned that convergently selected clonotypes
should have a lower generative probability than typical convergently recombined clonotypes. To test
this, we estimated the generative probability of the TCRβ/γ Complementarity Determining Region 3
(CDR3) amino-acid sequences that were shared between several patients. Since no algorithm exists
that can compute this generative probability directly, our method relies on the random generation
and translation of massive numbers of TCR nucleotide sequences using a mechanistic statistical
model of V(D)J recombination Murugan et al. (2012), as can be easily performed e.g. using the iGoR
software Marcou et al. (2017).

In Fig.2A we plot for each clonotype the number of donors sharing that clonotype against
its generation probability. Disease-specific TCRβ variants validated by functional tests in source
studies are circled in red. Note that validated disease-specific TCRβ sequences have a much lower
generation probability than the typical sequences shared by the same number of donors. We
developed a method of axis transformation (see Methods and Materials) to compare the model
prediction with data values on the same scale (Fig.2B), so that outliers can be easily identified by
their distance to identity line. Our method can be used to narrow down the potential candidates for
further experimental validation of responsive receptors. Additional information, like the expansion
of the identified TCRβ clonotype in the inflammation site, the presence of the same clonotype in the
repertoire of activated or memory T-cells, or absence in a cohort of healthy controls, could provide
additional evidence for functional association of identified candidates with a given condition.

Our method also identifies other significant outliers than reported in the source studies (shown
in red, and obtained after multiple-test correction – see Methods), which may have three possible
origins. First, they may be associated with the condition, but were missed by the source stud-
ies. Second, they may be due to other factors shared by the patients, such as features involved in
thymic or peripheral selection, or reactivity to other common conditions than CMV (e.g. influenza infection). Third, they can be the result of intersample contamination. Our approach is able to diagnose the last explanation by estimating the likelihood of sharing at the level of nucleotide sequences (i.e. synonymously), as detailed in the Methods section.

Discussion
Antigen receptor sequencing currently has little clinical applications. One of the most important ones is diagnostics and tracking of malignant T-cell and B-cell clones in lymphomas, where it allows for directly measuring the abundances of certain clones at different timepoints. Our method allows for a sequence-based theoretical prediction of T-cell abundances at the population level, and for the identification of T-cell clones associated with infectious and autoimmune conditions. Extensive databases of condition-associated clones can provide a means of disease diagnostics and extend the clinical utility of antigen receptor repertoire sequencing technologies.

This method may also be useful in the analysis of known antigen-specific TCR clonotypes. The typical source of such TCR sequences are MHC-multimer positive cells isolated from one or a few donors Shugay et al. (2017); Ticktisky et al. (2017). Some of these antigen-specific clonotypes are private, and are hard to find in other patients, providing limited diagnostic value. Our method is able to distinguish these clones from publicly responding clonotypes that are likely to be shared by many patients using only their CDR3 amino acid sequences.

The cohort size necessary for the identification of antigen-specific clonotypes with our method varies (see “Designing the experiment” subsection in Methods). It depends on the strength and diversity of the response to the given antigen. CMV and other Herpesviridae (EBV, HSV), are able to cause a persistent infection, and a large fraction of the TCR repertoire of CMV-positive donors are believed to be specific to them—on average, up to 10% of CD8+ cells are specific to a single CMV epitope in elderly individuals Khan et al. (2004). However, it was shown that in a human acute infection model of yellow fever vaccination, virus-specific T-cell clones are one of the most abundant in the TCR repertoire and occupy up to 12% of the CD8+ T-cell repertoire. This response is short-lived and contracts significantly a month after immunization Miller et al. (2008). So the peak of an immune response is the best timepoint to search for antigen-specific TCRs in acute infections using this method. T-cell response to herpesviruses is also not unique in terms of public clonotype involvement—in ankylosing spondylitis Faham et al. (2017), 30-40% of patients share a certain TCRγ aminoacid sequence, which is more than the fraction of patients sharing CMV-specific clonotypes that we analysed in this study.

Our approach can be used on other hypervariable receptor chains (TCRα, BCR heavy and light chains), as well as other species (mice, fish, etc.). Both α and β chains contribute to T-cell receptor specificity. Single-cell or paired sequencing technologies Zemmour et al. (2018) could identify partner receptor chains for condition-associated TCR α or β chain sequences identified with our approach. Antigenic peptides recognized by complete T-cell receptors could then be recovered in vitro using yeast-display libraries of peptide-MHC Gee et al. (2017). As paired sequencing becomes more widespread, our method can be extended to the analysis of full paired TCR by applying the exact same analysis using the joint recombination probability of αβ clonotypes.

Recent advances in computational methods allow us to extract TCR repertoires from existing RNA-Seq data Bolotin et al. (2017); Brown et al. (2015). Huge numbers of available RNA-Seq datasets from patients with various conditions can be used for analysis and identification of novel virus, cancer, and self reactive TCR variants using our method. The more immunoglobulin receptors with known specificity are found using this type of association mapping, the more clinically relevant information can be extracted from immunoglobulin repertoire data.
Materials and Methods

Statistical analysis

Problem formulation

Our framework is applicable to analyze the outcome of a next generation sequencing experiment probing the immune receptor repertoires of \( n \) individuals with a given condition, e.g. CMV or Type 1 diabetes. We denote by \( M_i \) the number of unique amino acid TCR sequences in patient \( i, i = 1, \ldots, N \).

For a given TCR amino acid sequence \( \sigma \), we set \( x_i = 1 \) to indicate that \( \sigma \) is present in patient \( i \)'s repertoire, and \( x_i = 0 \) otherwise. For a given shared sequence \( \sigma \), we want to know how likely its sharing pattern is under the null hypothesis of convergent recombination, correcting for the donors' different sampling depths. In other words, is \( \sigma \) overrepresented in the population of interest? If \( \sigma \) is significantly overrepresented, we also want to quantify the size of this effect.

Overview

Under the null hypothesis, the presence of \( \sigma \) in a certain number of donors is explained by independent convergent V(DJ) recombination events in each donor. Given the total number of recombination events that led to the sequenced sample of donor \( i, N_i \), the presence of given amino acid sequence \( \sigma \) in donor is Bernoulli distributed with probability

\[
p_i = (x_i) = \left(1 - P_{\text{post}}(\sigma)\right)^{N_i},
\]

\[
P_{\text{post}}(\sigma) = P_{\text{gen}}(\sigma) \times Q.
\]

where \( P_{\text{post}}(\sigma) \) is the model probability that a recombinated product found in a blood sample has sequence \( \sigma \) under the null hypothesis. It is formed by the product of \( P_{\text{gen}}(\sigma) \), the probability to generate the sequence \( \sigma \), estimated using a V(DJ) recombination model (see the following subsubsection), and \( Q \), a constant correction factor accounting for thymic selection (see Estimation of the correction factor \( Q \) subsubsection). The number of independent recombination events \( N_i \) leading to the observed unique sequences in a sample \( i \) is unknown, because of convergent recombination events within the sample, but it can be estimated from the number of unique sequences \( M_i \), using the model distribution \( P_{\text{post}} \) (see Estimation of \( N \), subsubsection).

We also calculate the posterior distribution of \( P_{\text{data}}(\sigma) \), corresponding to the empirical counterpart of \( P_{\text{post}}(\sigma) \) in the cohort, inferred from the sharing pattern of \( \sigma \) across donors. We use information about the presence of \( \sigma \) in our donors, \( x_1, \ldots, x_n \) and the sequencing depth for each donor, \( N_1, \ldots, N_n \) (see Estimation of \( P_{\text{data}}(\sigma) \) subsubsection), yielding the posterior density: \( p(P_{\text{data}}|x_1, \ldots, x_n) \).

Finally, we estimate the probability, given the observations, that the true value of \( P_{\text{data}} \) is smaller than the theoretical value \( P_{\text{post}} \) predicted using V(DJ) recombination model, analogous to a p-value and used to identify significant effects:

\[
P(P_{\text{post}} > P_{\text{data}}) = \int_0^{P_{\text{post}}} p(P_{\text{data}}|x_1, \ldots, x_n) dP_{\text{data}}.
\]

To estimate the effect size \( q(\sigma) \) we compare \( P_{\text{data}} \) to \( P_{\text{post}} \):

\[
q(\sigma) = \frac{P_{\text{data}}(\sigma)}{P_{\text{post}}(\sigma)}.
\]

Estimation of \( P_{\text{gen}} \), the probability of generation of a TCR CDR3 amino acid sequence

To procedure outlined above requires to calculate \( P_{\text{gen}}(\sigma) \), the probability to generate a given CDR3 amino acid sequence. Methods exist to calculate the probability of TCR and BCR nucleotide sequences from a given recombination model Murugan et al. (2012); Marcou et al. (2017), but are impractical to calculate the probability of amino acid sequences, because of the large number of codon combinations that can lead to the same amino acid sequence, \( \Pi_{\sigma} n_{\text{codon}}(r) \), where \( L \) is the sequence length, and \( n_{\text{codon}}(r) \) the number of codons coding for amino acid \( r \). The number is about \( 1.4 \times 10^7 \) for a typical CDR3 length of 15 amino acid.
Instead, we estimated $P_{\text{gen}}(\sigma)$ using a simple Monte-Carlo approach. We randomly generated a massive number ($N_{\text{sim}} = 2 \times 10^9$) of recombination scenarios according to the validated recombination model Murugan et al. (2012):

$$P_{\text{rearr}}(r) = P(V)P(D, J)P(\text{del}V|V)P(\text{ins}V D) \times P(\text{del}D 1, \text{del} Dr|D)P(\text{ins} DJ P(\text{del} J |J).$$

The resulting sequences were translated, truncated to only keep the CDR3, and counted. $P_{\text{gen}}(\sigma)$ was approximated by the fraction of events thus generated that led to sequence $\sigma$. This approximation becomes more accurate as $N_{\text{sim}}$ increases, with an error on $P_{\text{gen}}(\sigma)$ scaling as $(P_{\text{gen}}(\sigma)/N_{\text{sim}})^{1/2}$.

### Estimation of the correction factor $Q$

Not all generated sequences pass selection in the thymus. $P_{\text{gen}}$ systematically underestimates the frequency of recombination event that eventually make it into the observed repertoire. To correct for this effect, we estimate a correction factor $Q$, as was suggested in Elhanati et al. (2014):

$$P_{\text{post}}(\sigma) = P_{\text{gen}}(\sigma) \times Q.$$  

Contrary to Elhanati et al. (2014), which learned a sequence-specific factor for each individual, here we assume that all observed sequences passed thymic selection. $Q$ is a normalization factor accounting for the fact that just a fraction $Q^{-1}$ of sequences pass thymic selection. This factor is determined for each VJ-combination as an offset when plotting $\log P_{\text{gen}}$ against $\log P_{\text{data}}$ (see the following subsection for definition of $P_{\text{data}}$), using least squares fitting.

### Estimation of $P_{\text{data}}(\sigma)$, the probability of sequence occurrence in data

The variable $x_i$ indicates the presence or absence of a given TCR amino acid sequence $\sigma$ in the $i$th dataset with $N_i$ recombination events per donor. We want to estimate $P_{\text{data}}(\sigma)$, which is a fraction of recombination events leading to $\sigma$ in the population of interest. According to Bayes' theorem, for a given $\sigma$, the probability density function of $P_{\text{data}}$ reads:

$$\rho(P_{\text{data}}|x_1, \ldots, x_n) = \frac{\mathbb{P}(x_1, \ldots, x_n|P_{\text{data}}) \rho_{\text{prior}}(P_{\text{data}})}{\int_0^1 \mathbb{P}(x_1, \ldots, x_n|P_{\text{data}}) \rho_{\text{prior}}(P_{\text{data}}) dP_{\text{data}}}.$$  

The likelihood is given by a product of Bernoulli probabilities:

$$\mathbb{P}(x_1, \ldots, x_n|P_{\text{data}}) = \prod_{i=1}^N \left[ 1-(1-P_{\text{data}})^N \right]^{x_i} \left[ (1-P_{\text{data}})^N \right]^{1-x_i},$$

and a flat prior $\rho_{\text{prior}}(P_{\text{data}}) = \text{const}$ is used.

We estimate $P_{\text{data}}^*$ (shown in Fig. 2B) as the maximum of the posterior distribution:

$$P_{\text{data}}^* = \arg \max_{P_{\text{data}}} \rho(P_{\text{data}}|x_1, \ldots, x_n).$$

### Estimation of $N_i$, the number of recombination events

The total number $N_i$ of recombination events in $i$th dataset is unknown, but we can count the number of unique CD3 acid sequences $M_i$ observed in the sequencing experiment. For a typical TRB experiment, convergent recombination is relatively rare and one could use $N_i \approx M_i$ as an approximation. However, for less diverse loci (e.g. TRA), or for much higher sequencing depths, one should correct for convergent recombination, as the observed number of unique amino acid sequences could be much lower than the actual number of corresponding recombination events.

The average number of unique sequences resulting from $N_i$ recombination events is, in theory:

$$\langle M_i \rangle = \sum_{\sigma \in T} (1-P_{\text{post}}(\sigma))^{N_i}.$$
sequences for which $P_{\text{gen}}$ is estimated as explained above. We take $T$ to be a random subset of unique sequences, $T \subset \{\sigma_1, \ldots, \sigma_{N_{\text{uni}}}\}$, of size $|T| = N_{\text{uni}}/Q$, and we apply Eq. 10.

Using this equation we plot the calibration curve for the TRBV5-1 TRBJ2-6 VJ datasets in Fig. 3. For comparison the case of no thymic selection ($Q = 1$) is shown in red. The inversion of this curve yields $N_i$ as a function of $M_i$.

![Figure 3. Calibration curve for TRBV5-1 TRBJ2-6 combination. Here we plot the fraction of unique amino acid sequences to recombination events against the logarithm of the number of recombination events. The blue line corresponds to the theoretical solution with selection, the red line corresponds to the theoretical solution without selection.](image)

**Pipeline description**

In this section we describe how to apply our algorithm to real data. All the code and data necessary to reproduce our analysis is available online on github [https://github.com/pogorely/vdjRec/](https://github.com/pogorely/vdjRec/).

We start with annotated TCR datasets (CDR3 amino acid sequence, V-segment, J-segment), one per donor. Such datasets are produced by MiXCR Bolotin et al. (2015), immunoseq [http://www.adaptivebiotech.com/immunoseq] and most other software for NGS repertoire data preprocessing. Data we used was in immunoseq format, publicly available from [https://clients.adaptivebiotech.com/immuneaccess](https://clients.adaptivebiotech.com/immuneaccess) database.

We proceed as follows:

1. Split datasets by VJ combinations. The resulting datasets correspond to lists of unique CDR3 amino acid sequences for each donor and VJ combination. All following steps should be done independently for each VJ combination.

2. (Optional). Filter out sequences present in only one donor to speed up the downstream analysis.

3. Generate a large amount of simulated nucleotide TCR sequences for a given VJ combination. Extract and translate their CDR3, and count how many times each sequence appears in the simulated set (restricting to sequences actually observed in donors for better efficiency). The resulting number divided by the total number of simulated sequences is an estimate of $P_{\text{gen}}$.

4. Estimate $P_{\text{data}}$ for each sequence in the dataset, see *Estimation of $P_{\text{data}}$*(σ) *subsubsection*. 

![Diagram](image)
5. Using $P^*$ and $P_{\text{gen}}$, estimate for each VJ combination the normalization $Q$ by minimizing

$$
\sum_{j=1}^{n} \left( \log P^*_{\text{data}}(\sigma_j) - \log P_{\text{gen}}(\sigma_j) - \log Q \right)^2,
$$

where $\sigma_j, j = 1, \ldots, n$ are the shared sequences.

6. Calculate $P_{\text{post}} = Q \times P_{\text{gen}}$. Calculate the p-value (Eq. 3) and effect size (Eq. 4).

### Usage example

#### Data sources

Data from Emerson et al. (2017) and Seay et al. (2016) is publicly available from the immuneaccess database: [https://clients.adaptivebiotech.com/immuneaccess](https://clients.adaptivebiotech.com/immuneaccess). For our analysis, we only considered VJ combinations for which the authors identified condition-associated clonotypes with MHC-multimer proved specificity. CDR3 aminoacid sequences and V and J segment of these TCR clonotypes are given in Table 1.

<table>
<thead>
<tr>
<th>CDR3aa</th>
<th>V-segment</th>
<th>J-segment</th>
<th>Antigen source</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>CASSLAPGATNEKLFF</td>
<td>TRBV07-06</td>
<td>TRBJ1-4</td>
<td>CMV</td>
<td>Emerson et al. (2017)</td>
</tr>
<tr>
<td>CASSPQEGANVLTF</td>
<td>TRBV05-01</td>
<td>TRBJ2-6</td>
<td>CMV</td>
<td>Emerson et al. (2017)</td>
</tr>
<tr>
<td>CASASYGTYTF</td>
<td>TRBV12-3,-4</td>
<td>TRBJ1-2</td>
<td>CMV</td>
<td>Emerson et al. (2017)</td>
</tr>
<tr>
<td>CASSLVGGPSEAFF</td>
<td>TRBV05-01</td>
<td>TRBJ1-1</td>
<td>self</td>
<td>Seay et al. (2016); Gebe et al. (2009)</td>
</tr>
</tbody>
</table>

Table 1. Published antigen-specific clonotypes used to test the algorithm.

#### Analysis results

We applied our pipeline to identify CMV-specific and self-specific TCR sequences listed in Table 1. For our analysis we used only case cohorts, without controls. For each dataset we followed our pipeline described in subsubsection. We found that sequences reported in the source studies as being both significantly enriched in the patient cohort, and antigen-specific according to MHC-multimers, were the most significant in 3 out of 4 datasets. In the remaining TRBV12 dataset, the sequence of interest was the top 40 most significant out of 27,699 sequences present in at least two CMV-positive donors.

<table>
<thead>
<tr>
<th>CDR3aa</th>
<th>V</th>
<th>J</th>
<th>Ag.source</th>
<th>p-value rank</th>
<th>p-value</th>
<th>Effect size</th>
</tr>
</thead>
<tbody>
<tr>
<td>CASSLAPGATNEKLFF</td>
<td>07-06</td>
<td>1-4</td>
<td>CMV</td>
<td>1/1637</td>
<td>$1.2 \times 10^{-17}$</td>
<td>8.8</td>
</tr>
<tr>
<td>CASSPQEGANVLTF</td>
<td>5-01</td>
<td>2-6</td>
<td>CMV</td>
<td>1/5549</td>
<td>$1.8 \times 10^{-17}$</td>
<td>42.3</td>
</tr>
<tr>
<td>CASASYGTYTF</td>
<td>12-3,-4</td>
<td>1-2</td>
<td>CMV</td>
<td>40/27669</td>
<td>$2.5 \times 10^{-14}$</td>
<td>28.8</td>
</tr>
<tr>
<td>CASSLVGGPSEAFF</td>
<td>5-01</td>
<td>1-1</td>
<td>self</td>
<td>1/2646</td>
<td>$9.5 \times 10^{-19}$</td>
<td>524</td>
</tr>
</tbody>
</table>

Table 2. Output of the algorithm for sequences from table 1.

#### Identifying contaminations

Intersample contamination may complicate high-throughput sequencing data analysis in many ways. It could occur both during library preparation or the sequencing process itself Sinha et al. (2017). Contaminations have the same nucleotide and amino acid sequence in all datasets, and so our method identifies them as outliers, because their sharing cannot be explained by a high recombination probability.

Our method provides a tool to diagnose contamination. Given an amino-acid sequence present in many donors, we measure its theoretical nucleotide diversity using the same simulation approach we used to calculate the generative probability $P_{\text{gen}}$ of the amino acid sequence (see Estimation of $P_{\text{gen}}$ subsubsection). If the diversity of the simulated nucleotide sequences is much larger than observed in the data, it is a sign of contamination.
We applied this approach to the CDR3 sequence CASLVGPGSEAFF associated to Type 1 diabetes, and found 19 recombination events consistent with that amino acid sequence out of our simulated dataset. We found 18 different nucleotide variants out of the 19 total possible. In contrast, in the data this clonotype had the same nucleotide variant in all of the 8 donors in which it was present. That variant was absent from the simulated set. A one-sided Fisher exact test gives a $p < 10^{-6}$ probability of this happening by chance, indicating contamination as a likely source of sharing.

Designing the experiment

![Graphs showing simulation results for different cohort sizes, sequencing depths, effect sizes, and target clone abundances.](image)

Figure 4. Simulation of the method performance with different cohort sizes, sequencing depths, effect sizes and target clone abundances in population. In panels A, B, C, we plot the number of simulations (out of 100) where a clone with a given effect size $q$ (line color, see legend) and $P_{\text{data}}$ (x-axis) is found to be significant using our approach, for cohort sizes of 10, 30 and 100 donors respectively. Larger cohort sizes and effect sizes make it possible to resolve clonotypes with lower abundance in the population. In panel D, we show the effect of sequencing depth for fixed $q = 10$: larger numbers of clonotypes sequenced per donor allow us to resolve less frequent clones, since a clone of a given $P_{\text{data}}$ is detected in a larger fraction of donors (panel E).

Our approach also allows us to obtain important estimates for experiment design. A number of variables affect detection of an antigen-specific clone using our approach: the abundance of the clone in the general population (represented by $P_{\text{data}}$ in our approach), the cohort size, the sequencing depth $N_i$ in each donor in the cohort, and also the effect size. Fixing any two of these variables results in a constraint between the other two and the affects the probability to detect an antigen-specific clonotype, which translates into the statistical power of the method. As an example of such an analysis, we fix the cohort size at 10, 30 or 100 donors (see Fig. 4A, B, C respectively) and the sequencing depth at $N_i = 1000$ unique clones sequenced per repertoire for a given Vj-combination in each donor in the cohort. We ask how frequently a disease specific clone with $P_{\text{data}}$ abundance in the population and effect size $q = P_{\text{data}}/P_{\text{post}}$ is detected with our method. To address this question for each value $P_{\text{data}}$ we perform a simulation: we simulate $x_1, x_2, \ldots, x_n$
Bernoulli variables, each with a \( p_i = 1 - e^{-N_i P_{\text{data}}} \) success probability. For a given value of \( P_{\text{data}} \) and \( q \), there is a single value of \( P_{\text{post}} = P_{\text{data}}/q \). Then we calculate

\[
P(P_{\text{post}} > P_{\text{data}}) = \int_0^{P_{\text{post}}} \rho(P_{\text{data}} | x_1, \ldots, x_n) dP_{\text{data}},
\]

where \( \rho(P_{\text{data}} | x_1, \ldots, x_n) \) is the posterior density, and check if \( P(P_{\text{post}} > P_{\text{data}}) \) is below a significance threshold of 0.0001. Such a low significant threshold in this example is chosen to take into account the multiple testing correction: we assume that about 1000 shared clones would be tested in a such an analysis and \( p < 0.01 \) after multiple testing is chosen as the significance threshold in this study, which gives \( p < 0.0001 \) before the Bonferroni multiple testing correction. Then we plot the number of simulations in which a significant result was obtained for given effect size \( q \) and \( P_{\text{data}} \) for the clone of interest and the fraction of donors with this sequence in the simulated cohort (see Fig. 4E, blue curve). Unsurprisingly, the effect size plays a role in the probability to detect an antigen specific clone, and the detection is not possible at all if the clone is not shared between several donors in the cohort (in our example this happens for \( P_{\text{data}} < 10^{-3} \)) irrespective of the effect size. Larger cohort sizes can help to resolve clones with lower abundances, but sequencing depth also has a strong effect on the power of the approach. In Fig. 4D and E we show simulation results for a fixed \( q = 10 \) and different sequencing depths \( N_r \) of 100, 1000 or 10000 clones per donor in a given VDJ combination. Interestingly, a large sequencing depth (black curve) can lead to a situation when an abundant and frequently generated clone will not be detected by the algorithm, because it will be found in all donors in the cohort. An additional test that checks the predictions by lowering the sequencing depth \textit{in silico} by downsampling can solve this problem.

Another complicated question is how \( P_{\text{data}} \) is related to the number of clones and the fraction of the repertoire involved in the response to the infection in a given donor. If the same antigen-specific clone is present in every donor, \( P_{\text{data}} \) is close to the average abundance of this clone in the repertoire. However one can imagine an opposite situation where the response is so diverse and private that different clones respond to a given antigen in each donor. It was previously shown that the diversity and publicness of responding T-cell clonotypes varies a lot across antigens \textit{Dash et al.} (2017). Our approach is restricted to the identification of \textit{public} antigen-specific clonotypes, which may not exist for all antigens.

Acknowledgments

This work was supported by Russian Science Foundation grant N\#15-15-00178, and partially supported by European Research Council Consolidator Grant N\#724208.

References


Quigley MF, Greenaway HY, Venturi V, Lindsay R, Quinn KM, Seder Ra, Douek DC, Davenport MP, Price Da.


